42
Participants
Start Date
October 12, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
EXG102-031
EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injection.
NOT_YET_RECRUITING
Beijing Hospital, Beijing
NOT_YET_RECRUITING
Beijing Tongren Hospital,Cmu, Beijing
RECRUITING
Peking University People'S Hospital, Beijing
NOT_YET_RECRUITING
The Southwest Hospital of Amu, Chongqing
RECRUITING
Central theater General Hospital, Wuhai
NOT_YET_RECRUITING
Jiangsu Provinve Hospital, Nanjing
NOT_YET_RECRUITING
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
NOT_YET_RECRUITING
Eye Hospital,WMU, Wenzhou
Hangzhou Jiayin Biotech Ltd
INDUSTRY